Truist Securities analyst Neal Dingmann upgrades Centennial Resource Dev (NASDAQ:CDEV) from Hold to Buy.
New England Journal Of Medicine Publishes Results From Phase 3 Induction And Maintenance Programs Evaluating Upadacitinib In Crohn’s Disease
AbbVie (NYSE:ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, U-EXCEED and U-ENDURE – evaluating